Home
Welcome Note
Congress Chairpersons
Faculty
Scientific Program
Satellite Symposia
Timetable
Abstract submission
Poster List
Poster Preparation Guidelines
Registration
Invitation Letter
Accommodation
Princesa Sofia Hotel
Sponsorship & Exhibition
Sponsors
CME Accreditation
EACCME
EHA - CME
General Information
Before you travel...
Transportation
Tips and Hints
About Barcelona
Italian Agent
Endorsements
Partners
COHEM 2010
Past Sponsors
Contact Us
Gallery
 
  Scientific Program Print
Thursday, September 6, 2012
Hall A
 
15:30-17:45
PLENARY SESSION 1: DEBATES IN APL, AML & CLL
15:30-15:40
15:40-16:15
15:40-15:45
15:45-15:55
15:55-16:05
16:05-16:15
Chairpersons opening remarks
Is there a possibility to cure APL without chemotherapy in the future?
Moderator: G. Sagilo, Italy
Yes: M. A. Sanz, Spain
No: F. Lo-Coco, Italy
Discussion
16:15-17:00
16:15-16:20
16:20-16:30
16:30-16:40
16:40-17:00
Has molecular characterization of cytogenetically normal AML been a major advance in the management of patients?
Moderator: A.K. Burnett, UK
Yes: B. Falini, Italy
No: C. Schiffer, USA
Discussion
17:00-17:45
17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45
Should the new genetic abnormalities and prognostic factors change our management of CLL patients?
Moderator: R. Foà, Italy
Yes: S. Stilgenbauer, Germany
No: G. Gaidano, Italy
Discussion
 
 
17:45-18:15
Coffee Break
 
 
18:15-19:30
EMERGING STRATEGIES FOR RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA: ADDRESSING UNMET NEEDS
Satellite Symposium Sponsored by ARIAD Pharmaceuticals, Inc.
 
19:30-21:00
Welcome Reception

Friday, September 7, 2012

Hall A

08:30-10:00
SESSION 2: AML

08:30-09:15

08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
Should patients with high risk MDS (and AML in early relapse) proceed directly to allogeneic transplantation without prior induction chemotherapy?
Moderator: M.A. Sanz, Spain
Yes: A.K. Burnett, UK
No: P. Fenaux, France
Discussion
 
09:15-09:20

09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00
Should older patients with AML be considered for lower intensity approaches rather than 3 & 7?
Moderator: J. Esteve, Spain
Yes: J. Sierra, Spain
No: C. Schiffer, USA
Discussion
 
10:00-10:30
Coffee Break
 
10:30-12:00
SESSION 4: ALL

 

10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15
Should ‘pediatric’-like strategies be extended over the age of 35?
Moderator: D. Hoelzer, Germany
Yes: J.M. Ribera, Spain
No: J.P. Marie, France
Discussion
11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00
Can ALL be managed without chemotherapy / transplant?
Moderator: C. Schiffer, USA
Yes: R. Foà, Italy
No: D. Hoelzer, Germany
Discussion
 
12:00-13:00
Lunch Break
 
13:00-14:15
RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) AND ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): REDEFINING THERAPY FOR THESE DIFFICULT DISEASES

A prIME Oncology Symposium supported by Millennium: The Takeda Oncology Company

 
14:15-15:45
SESSION 6: MDS

 

14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00
Is iron chelation of importance in the management of myelodysplasia?
Moderator: G. Saglio, Italy
Yes: E. Rachmilewitz, Israel
No. C. Schiffer, USA
Discussion
15:00-15:45
15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45
After failure of hypomethylating agent-based therapy in myelodysplastic syndromes: which is the best strategy?
Moderator: C. Schiffer, USA
BMT: N. Kröger, Germany
Investigational drugs: V. Santini, Italy
Discussion
 
15:45-16:15
Coffee Break
 
16:15-17:45
SESSION 8: MPNs

16:15-17:00
16:15-16:20
16:20-16:30
16:30-16:40
16:40-17:00
Is the development of JAK 2 inhibitors an important advance in the treatment of MPNs?
Moderator: A. Vannucchi, Italy
Yes: G. Barosi, Italy
No. T. Barbui, Italy
Discussion
17:00-17:45
17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45
Is the recommended hematocrit target in polycythemia vera evidence-based?
Moderator: R. Hehlmann, Germany
Yes: A. Vannucchi, Italy
No: T. Barbui, Italy
Discussion

Hall B

08:30-10:00
SESSION 3: CLL

 

08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
Monoclonal B-cell lymphocytosis: Much ado about nothing?
Moderator: R. Foà, Italy
Yes: E. Montserrat, Spain
No: A.C. Rawstron, UK
Discussion
09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00
Is the whole better than the sum of its parts? All ‘fit’ older patients should receive FCR.
Moderator: E. Montserrat, Spain
Yes: S. Stilgenbauer, Germany
No: R. Foà, Italy
Discussion
10:00-10:30
Coffee Break
 
10:30-12:00
SESSION 5: INDOLENT NON-HODGKIN LYMPHOMAS

 

10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15
Should all patients with follicular leukemia receive maintenance therapy?
Moderator: A. Hagenbeek, The Netherlands
Yes: U. Vitolo, Italy
No: E. Kimby, Sweden
Discussion
11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00
Is there a role of HDT-ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era?
Moderator: N. Kröger, Germany
Yes: B. Coiffier, France
No: A. Hagenbeek, The Netherlands
Discussion
12:00-13:00
Lunch Break
 
14:15-15:45
SESSION 7: HODGKIN'S DISEASE

 

14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00
Do we have one or two shots for cure in advanced Hodgkin’s disease? Kairos or Chronos?
Moderator: P.L. Zinzani, Italy
Pro Chronos: late intensification: J. Connors, Canada
Pro Kairos: early intensification: A. Engert, Germany
Discussion
 
15:00-15:45
15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45
Should therapy for HD be modified by the results of the early PET?
Moderator: J. Connors, Canada
Yes: P.L. Zinzani, Italy
No: A. Engert, Germany
Discussion
 
15:45-16:15
Coffee Break
 
16:15-17:45
SESSION 9: AGGRESSIVE LYMPHOMAS
 
16:15-17:00
16:15-16:20
16:20-16:30
16:30-16:40
16:40-17:00
Is there a role for RT in localized DLBCLs?
Moderator: C. Haioun, France
Yes: J. Yahalom, USA
No: B. Coiffier, France
Discussion
 
17:00-17:45
17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45
Is there a role for ASCT for the initial management of high risk DLBCLs?
Moderator: B. Coiffier, France
Yes: C. Haioun, France
No: J. Connors, Canada
Discussion
 
 
 

Saturday, September 8, 2012

Hall A
 
08:30-10:00
SESSION 10: CML

08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
Are TKI sufficient for the treatment of CML, or should TKI be combined with other agents or treatment modalities?
Moderator: G. Saglio, Italy
Yes: R. Hehlmann, Germany
No: M. Baccarani, Italy
Discussion
09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00
Should patients treated with second line TKIs be considered for allo BMT?
Moderator: R. Hehlmann, Germany
Yes: E. Olavarria, Spain
No: J.L. Steegmann, Spain
Discussion
 
10:00-10:30
Coffee Break

10:30-12:00
SESSION 12: HEMOGLOBINOPATHIES

 

10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15
Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors?
Moderator: E. Rachmilewitz, Israel
Yes: E. Angelucci, Italy
No: G. Rodgers, USA
Discussion
11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00
Is there a rationale for treatment of sickle cell anemia except for acute complications?
Moderator: G. Rodgers, USA
Yes: S. Sheth, USA
No: J.L. Vives Corrons, Spain
Discussion
12:00-13:00
Lunch Break
 
13:00-14:15
CONTEMPORARY MANAGEMENT OF CHRONIC PHASE CML: BROADENING THE PLAYING FIELD

A prIME Oncology Symposium supported by Teva Oncology

 
14:15-15:45
SESSION 14: BIOMARKERS

 

14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00
Are the new molecular and cytogenetic markers useful for the management of MNPs? Moderator: G. Saglio, Italy
Yes: W. Vainchenker, France
No: G. Barosi, Italy
Discussion
15:00-15:45
15:00-15:05 15:05-15:15
15:15-15:25 15:25-15:45
Is serum ferritin a sufficient marker for evaluation and monitoring treatment of iron overload?
Moderator: E. Rachmilewitz, Israel
Yes: A. Piga, Italy
No: Y. Cabantchik, Israel
Discussion
15:45-16:15
Coffee Break

16:15-17:30
PLENARY SESSION 16: DEBATES IN MM & CML

16:15-16:50
16:15-16:20
16:20-16:30
16:30-16:40
16:40-16:50
Preferred 1st line treatment of CML: 2nd generation TKI or optimized Imatinib?
Moderator: J.L. Steegmann, Spain
2nd generation TKI: G. Saglio, Italy
Optimized Imatinib: R. Hehlmann, Germany
Discussion
16:50-17:25
16:50-16:55
16:55-17:05
17:05-17:15
17:15-17:25
MM - Cure versus control: Which is the best strategy?
Moderator: J.F. San-Miguel, Spain
Cure: B. Barlogie, USA
Control: M. Boccadoro, Italy
Discussion
17:25-17:30
Closing Address

Hall B
 
08:30-10:00
SESSION 11: MULTIPLE MYELOMA

 

08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
Transplant in MM patients: Early versus late
Moderator: J.F. San-Miguel, Spain
Early: A. Nagler, Israel
Late: M. Boccadoro, Italy
Discussion
09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00
Is there a role for maintenance therapy?
Moderator: M. Boccadoro, Italy
Yes: A. Palumbo, Italy
No: J.F. San-Miguel, Spain
Discussion
10:00-10:30
Coffee Break
 
10:30-12:00
SESSION 13: INFECTIONS

10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15
Should anti-infection prophylaxis be given before / after BMT ?
Moderator: A. Nagler, Israel
Yes: R. Martino, Spain
No: E. Olavarria, Spain
Discussion
11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00
Are all the GFs the same?
Moderator: R. Martino, Spain
Yes: G. Gaidano, Italy
No: M. Shapiro, Israel
Discussion
12:00-13:00
Lunch Break
 
14:15-15:45
SESSION 15: COAGULATION

 

14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00
What should be the next step after failure of steroids in ITP – splenectomy versus Rituximab or TPO mimetics?
Moderator: M.M. Samama, France
Splenectomy & Rituximab: R. Stasi, UK
TPO mimetics: N. Cooper, UK
Discussion
 
15:00-15:45
15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45
New anticoagulants: Monitoring or not Monitoring?
Mod: N. Cooper, UK
Monitoring: M.M. Samama, France
Not Monitoring: A. Falanga, Italy
Discussion

Home    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 12/04/2013 Created by     WebStudio.co.il